<SEC-DOCUMENT>0001193125-24-267132.txt : 20241127
<SEC-HEADER>0001193125-24-267132.hdr.sgml : 20241127
<ACCEPTANCE-DATETIME>20241127160526
ACCESSION NUMBER:		0001193125-24-267132
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241127
DATE AS OF CHANGE:		20241127

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AIM ImmunoTech Inc.
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				520845822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-27072
		FILM NUMBER:		241511007

	BUSINESS ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		352-448-7797

	MAIL ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEMISPHERX BIOPHARMA INC
		DATE OF NAME CHANGE:	19950614

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KELLNER TED D
		CENTRAL INDEX KEY:			0001187524
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		DFAN14A

	MAIL ADDRESS:	
		STREET 1:		C/O T&M PARTNERS
		STREET 2:		790 N. WATER ST. #2175
		CITY:			MILWAUKEE
		STATE:			WI
		ZIP:			53202
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>d869636ddfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<HTML><HEAD>
<TITLE>DFAN14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Rule <FONT STYLE="white-space:nowrap">14a-101)</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&#8194;&#9746; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B><B>&nbsp;</B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Under Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AIM IMMUNOTECH INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TED D. KELLNER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TODD
DEUTSCH </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROBERT L. CHIOINI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAUL W. SWEENEY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of
Persons(s) Filing Proxy Statement, if Other Than the Registrant) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ted D. Kellner, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (the &#147;Kellner Group&#148;) have
filed a definitive proxy statement and accompanying<B> GOLD</B> proxy card with the Securities and Exchange Commission (&#147;SEC&#148;) to be used to solicit votes for their election to the Board of Directors of AIM Immunotech Inc., a Delaware
corporation (the &#147;Company&#148; or &#147;AIM&#148;), at the 2024 Annual Meeting of Stockholders scheduled to be held on December&nbsp;17, 2024 (the &#147;Annual Meeting&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;27, 2024, the Kellner Group issued the letter that appears below and expects to distribute copies to stockholders by mail and electronically:
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Kellner Group Urges Stockholders of AIM Immunotech to Vote Enclosed <U>Gold Card</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The AIM Board has been in Control for Almost 9 Years and has Failed Epically for Stockholders </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Racked up over $100 Million in Net Losses</I></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Failed to Complete a Single Company-Sponsored Clinical Study</I></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Caused the AIM Share Price to Lose More than 99% of its Value</I></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Engaging in Gross Waste in a Self-Interested Entrenchment Campaign that has Brought AIM to the Brink of
Insolvency</I></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Incumbent Board Breached Duty of Loyalty to Stockholders (as ruled by the Delaware Supreme Court) in the
Process</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote for Kellner Group Nominees Now for Desperately Needed Change before it is Too Late </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;27, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear AIM Stockholders: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively,
the &#147;Kellner Group,&#148; &#147;we&#148; or &#147;us&#148; and, as nominees, the &#147;Kellner Group Nominees&#148;), are writing you today regarding the 2024 Annual Meeting of Stockholders of AIM ImmunoTech Inc., a Delaware corporation
(&#147;AIM&#148; or the &#147;Company&#148;), to solicit your vote to elect each of us to AIM&#146;s Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should have already received the
Kellner Group&#146;s proxy statement and we urge you to read it carefully because it contains important information. Please refer to the end of this letter for information about where you can find additional information. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr.&nbsp;Kellner is one of AIM&#146;s largest stockholders and has held his shares for several years. Mr.&nbsp;Deutsch is also one of AIM&#146;s largest
stockholders and has also held his shares for several years. Collectively, the Kellner Group is AIM&#146;s largest stockholder. The Kellner Group is aligned with AIM stockholders and has no motivations other than to improve the Company&#146;s
performance. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After nine years of terrible management and execution by the entrenched Board, who continue to mislead stockholders and keep them in the
dark, Board refreshment with new directors who have a vested interest in the success of AIM is the only way AIM can reverse its misfortune and see its share price increase. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We urge AIM stockholders to disregard the incumbent Board&#146;s baseless and misleading attempts to
question our motivations. This is nothing more than an effort to divert attention from the incumbent&#146;s Board&#146;s numerous failures and improper actions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Incumbent Board Has Failed AIM Stockholders and Destroyed Value </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <U>incumbent Board has controlled AIM for almost nine years and the results speak for themselves</U>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AIM&#146;s stock price has declined <B><U>by more than 99%</U></B>, and it continues its free fall &#150;
declining by approximately 40% in 2024 alone.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Net losses totaling over $120M have occurred from 2016 through June&nbsp;30, 2024 and are accelerating.<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">G&amp;A spending is excessive and increasing, driven largely by entrenchment efforts, going from
$8.67&nbsp;million in 2021 to $21.1&nbsp;million in 2023.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:2%">


<IMG SRC="g869636dsp04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Excessive G&amp;A expense comes at the expense of research and clinical development (R&amp;D) for Ampligen, with
R&amp;D expenses consistently falling below G&amp;A (approximately half in recently reported periods).<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this performance, AIM&#146;s financial condition has deteriorated severely: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of September&nbsp;30, 2024, effective liquidity was less than $1.0&nbsp;million (cash and equivalents plus
marketable securities, minus accounts payable).<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>AIM&#146;s management has raised substantial doubt about AIM&#146;s ability to continue as a going concern
and AIM&#146;s stockholders&#146; equity is below the minimum requirement for continued listing on the NYSE American stock exchange</U></B>.<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><U>AIM&#146;s situation is dire, and drastic change is needed immediately before it is too late</U>.
</B></P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stock prices included herein are based on historical data available at nyse.com, which data with respect to the
Company account for reverse stock splits of 1 for 12 in 2016 and 1 for 44 in 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the definitive proxy statement filed by the Kellner Group with the Securities and Exchange Commission (the
&#147;SEC&#148;) on November&nbsp;6, 2024 (the &#147;Proxy Statement&#148;), pg. 17; see also the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the Proxy Statement, pg. 14. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the Proxy Statement, pg. 14. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the Condensed Consolidated Balance Sheets included in the Company&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2024 filed with the SEC on November&nbsp;14, 2024 (&#147;2024 Third Quarter <FONT STYLE="white-space:nowrap">10-Q&#148;).</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the 2024 Third Quarter <FONT STYLE="white-space:nowrap">10-Q.</FONT>
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incumbent Board has squandered its cash and failed to complete a single relevant Company-sponsored
Ampligen clinical study and has funded its massive losses and wasteful spending with dilutive and expensive financings. This has been going on for years. As of the record date for the annual meeting, there were 63.7&nbsp;million shares outstanding
&#150; more than 100x dilution since the incumbent Board took control.<SUP STYLE="font-size:75%; vertical-align:top">7</SUP> <B><U>And AIM stockholders have</U></B><B><U></U></B><B><U>&nbsp;nothing to show for this massive dilution &#150; a 99+%
decline in value, a lack of clinical progress and a company on the brink of insolvency</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This gross financial mismanagement comes at the expense
of clinical development. AIM has been developing Ampligen for decades. Yet, after almost nine years under the control of the incumbent Board, we see no clear path to FDA approvals or commercialization. AIM&#146;s most recent Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> does not mention any plans Phase 3 studies, and it is not even clear when disclosed Phase 1 and 2 studies will be completed or next steps. AIM&#146;s strategy is characterized by shifting focuses with no follow
through, hoping to draw positive attention with press releases from time to time, but no clear timelines or goals toward regulatory approval and generating sales. <B><U>With no revenues, dwindling cash resources, unsustainable financing sources and
a stagnant clinical program, change is desperately needed</U></B><B>.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Incumbent Board Breached Its Fiduciary Duties and Engaged in Gross Waste
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Delaware Supreme Court ruled in 2024 that the incumbent Board breached its fiduciary duties. In describing
the Board&#146;s adoption of amended bylaws, the court stated that the &#147;<B><U>primary purpose was to interfere with Kellner&#146;s nomination notice, reject his nominees, and maintain control</U></B>&#148; and that the bylaws were
&#147;<B><U>product of an improper motive and purpose, which constitutes a breach of the duty of loyalty</U></B>.&#148;<I> (emphasis added)</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This illegal behavior by the AIM Board was not an isolated incident. A federal district court in Florida
sanctioned AIM and its counsel in 2024 in its Section&nbsp;13(d) claims against members of the Kellner Group and others &#150; claims that have been dismissed multiple times &#150; for pursuing arguments that were &#147;factually and legally
frivolous and <B><U>advanced for an improper purpose</U></B>.&#148; <I>(emphasis added)</I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incumbent Board is engaged in gross
waste in pursuit of this improper purpose. Based on AIM&#146;s own disclosures, we estimate that <B><U>the incumbent Board has spent between $15 to $20</U></B><B><U></U></B><B><U>&nbsp;million in just the past approximately two years in their bad
faith effort to prevent a meaningful election of directors and maintain control</U></B>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top">8</SUP> This is an unconscionable amount for a company of
AIM&#146;s size &#150; <B><U>approximately equal to or greater than its entire market capitalization</U></B>. We believe the incumbent Board bears sole responsibility for this waste&#151;the incumbent directors initiated and continued this effort in
order to entrench themselves and disenfranchise stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Board acting in good faith could justify these actions. <B><U>But for the incumbent
Board,</U></B><B><U></U></B><B><U>&nbsp;which has overseen a massive destruction in stockholder value and 99+% stock price decline under its control, to engage in this bad faith effort is completely shocking and disqualifying</U></B><B>. </B>The
Board&#146;s bad behavior is either intentional or due to incompetence, or a combination of both, either way the incumbent Board has failed miserably and must be dismissed immediately. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Incumbent Board Has No Strategic Plan and Will Not Change Their Destructive Course </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AIM&#146;s mismanagement and lack of progress has been overseen by the incumbent Board. The incumbent Board has been in control of AIM for almost 9 years, with
Equels, Mitchell and Appelrouth having been involved with AIM and each other going back years before then. Bryan is new to the Board, but had a prior relationship with Equels and was hand-picked by him, without any independent search, and has joined
right in with the others<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After decades of reckless oversight and gross mismanagement, the results are clear: an epic failure. The entrenched
incumbent Board has no plan to change their destructive course, no strategic business plan, no initiatives for independent oversight, no plan for proper governance, no plan to reduce excessive compensation, no plan for a focused </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2015 filed with the SEC on March&nbsp;29, 2016, with such number adjusted to account for reverse stock splits of 1 for 12 in 2016 and 1 for 44 in 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents Kellner Group estimate based on increase in Company&#146;s G&amp;A expense from 2021 to 2023 and
explanations provided as disclosed in AIM&#146;s Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for past two years, together with continued elevated G&amp;A expenses in 2024 to date as disclosed AIM&#146;s most recent Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical strategy and targeted R&amp;D, no plan to reduce wasteful G&amp;A spending, no plan for transparency for current stockholders, and no plan to attract long-term investors. <B><U>Their
only plan is more of the same, maintaining control at all costs while the company suffers and claiming clinical progress is somehow perpetually around the corner.</U></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Kellner Group Nominees are the Only Option to Turn Around AIM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collectively, the Kellner Group Nominees would bring a wealth of business, financial, clinical trial, life science and corporate governance experience and much
needed credibility to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike the incumbent Board, the Kellner Group Nominees have a plan: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary of Full Board Strategic Review of the Most Important Issues Plaguing AIM Today </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Complete&nbsp;Review&nbsp;of Ampligen and invest resources in the most promising applications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Leverage internal and external resources to review the numerous different
indications of Ampligen</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Create real, focused clinical strategy to help patients and stockholders</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Review of excessive G&amp;A spending and current levels of R&amp;D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Reallocate spending from G&amp;A to R&amp;D</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cut back on excessive
G&amp;A spending, starting with excessive compensation and legal spending</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Right size and focus R&amp;D as dictated by comprehensive review of Ampligen</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Review of Financing and Investor Communications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Leverage director expertise and networks to create financial plan to
ensure AIM can continue to operate in future years without taking on costly and overly dilutive financing</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Actually communicate with shareholders AIMs plans and begin to rebuild trust</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Review Management and Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Review current management and key personnel</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Attempt to work
constructively with current team to ensure sufficient continuity</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;If this is not possible, the Kellner Group has the experience and background to lead a turn
around</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;If it
becomes necessary, Mr.&nbsp;Chioini is committed to doing whatever the Board needs, including serving as interim CEO while Board runs a succession process</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Review of Governance &amp; Executive Compensation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Rectifying AIM&#146;s abysmal governance track record and excessive
compensation practices.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Identify an additional independent director to add to the Board, with a focus on finding a
candidate with no past history with AIM, with scientific or other relevant expertise, and with a diverse background</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE KELLNER GROUP URGES ALL STOCKHOLDERS TO VOTE ON THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENCLOSED <U>GOLD</U>&nbsp;PROXY CARD </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TODAY TO ELECT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TED D.
KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL SWEENEY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>If you have any questions, require assistance in voting
your</I><B><I>&nbsp;GOLD</I></B><I></I><B><I></I></B><I>&nbsp;proxy card, or need additional copies of the Kellner Group&#146;s proxy materials, please contact Okapi Partners at the phone numbers or email address listed below. Please also visit
<U>https://okapivote.com/AIM/</U> for additional information. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Thank you for your support. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Kellner Group </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Okapi Partners LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1212 Avenue of the Americas, 17th
Floor, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may <FONT
STYLE="white-space:nowrap">call&nbsp;toll-free:&nbsp;(844)&nbsp;343-2621</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Banks and
<FONT STYLE="white-space:nowrap">brokers&nbsp;call:&nbsp;(212)&nbsp;297-0720</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: info@okapipartners.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information and Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kellner Group has filed a definitive proxy statement and associated<B></B><B>&nbsp;GOLD</B>&nbsp;proxy card with the Securities and Exchange Commission
(&#147;SEC&#148;) to be used to solicit votes for the election of its slate of highly-qualified director nominees at the upcoming annual meeting of stockholders of AIM. Details regarding the Kellner Group nominees are included in its proxy
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE KELLNER GROUP STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the identity of participants in the Kellner Group&#146;s solicitation, and their
direct or indirect interests, by security holdings or otherwise, is set forth in the Kellner Group&#146;s proxy statement. Stockholders can obtain a copy of the proxy statement, and any amendments or supplements thereto and other documents filed by
the Kellner Group with the SEC for no charge at the SEC&#146;s website at www.sec.gov. Copies will also be available at no charge at the following website: https://www.okapivote.com/AIM. Investors can also contact Okapi Partners LLC at the telephone
number or email address set for the above. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g869636dsp04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g869636dsp04.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_PH -T_P#SSC_[[/\ A0 ;I_\
MGG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_WV?\ "@ W3_\ /./_ +[/^% !
MNG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_PH -T_P#SSC_[[/\
MA0 ;I_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_WV?\ "@ W3_\ /./_
M +[/^% !NG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_PH -T_P#S
MSC_[[/\ A0 ;I_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_WV?\ "@ W
M3_\ /./_ +[/^% !NG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_P
MH -T_P#SSC_[[/\ A0 ;I_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_W
MV?\ "@ W3_\ /./_ +[/^% !NG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YY
MQ_\ ?9_PH -T_P#SSC_[[/\ A0 ;I_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I
M_P#GG'_WV?\ "@ W3_\ /./_ +[/^% !NG_YYQ_]]G_"@!&DE3!:-,9 X<]S
MCTH ?*YC3<!DY  )QU.* &[I_P#GG'_WV?\ "@ W3_\ /./_ +[/^% !NG_Y
MYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_PH -T_P#SSC_[[/\ A0 ;
MI_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_WV?\ "@ W3_\ /./_ +[/
M^% !NG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_PH -T_P#SSC_[
M[/\ A0 ;I_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_WV?\ "@ W3_\
M/./_ +[/^% !NG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\ ?9_PH -T
M_P#SSC_[[/\ A0 ;I_\ GG'_ -]G_"@ W3_\\X_^^S_A0 ;I_P#GG'_WV?\
M"@ W3_\ /./_ +[/^% !NG_YYQ_]]G_"@ W3_P#/./\ [[/^% !NG_YYQ_\
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M_P ?NY]\YYS6KV?J[>FFWE>YDKW5][*_KK^)TE061;9_^>D?_?!_QH -L_\
MSTC_ .^#_C0 ;9_^>D?_ 'P?\: #;/\ \](_^^#_ (T &V?_ )Z1_P#?!_QH
M -L__/2/_O@_XT &V?\ YZ1_]\'_ !H -L__ #TC_P"^#_C0 ;9_^>D?_?!_
MQH -L_\ STC_ .^#_C0 ;9_^>D?_ 'P?\: #;/\ \](_^^#_ (T &V?_ )Z1
M_P#?!_QH -L__/2/_O@_XT &V?\ YZ1_]\'_ !H -L__ #TC_P"^#_C0 ;9_
M^>D?_?!_QH -L_\ STC_ .^#_C0 ;9_^>D?_ 'P?\: #;/\ \](_^^#_ (T
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M0R[36;U/$]QI=\(# Q(MI8T*DL%#%6RQR<-VQ]TTH:Q=]U_7]>HY^ZU;9_\
M!M^3&1>()IO$-_ SP6^EV4(D:5U)9^6!(;.  5(Z'I23O!R8VK220R/5+J;6
M--AL]1$UE=6,DB2/"-S,I7#'&/[W0 4.ZY_))BNO=?FQ?#VNK?6.DK>ZC_Q,
M;B-Y#"JJ/, )&2,< 8XY'XU;M?3LG^0M5H^[7W7+I\4Z*F\O?+&JJ7#R(RJX
M!P2K$8?_ (#FHOI<JVMAZ>)-)D25ENCB)%D/[IQN5CA2O'S9/'RYYXJFFOR$
MM?S+UK=PWL/FP,Q4$J=R%2".H((!!I6 GH * "@ H * "@"*Y_X]9O\ </\
M*@"6@")O^/J/_<;^:T 2T 5(-0T^6>ZC@N8&E@/[\*PRAQ_%^'\J5]+] ZVZ
MA!<6-ZBWUO<13QH"!+'(&0>O0XIOW=6&^B#^U-/^SQ7 O[;R96V1R>:NUV]
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MA(6$3E$#M@X4G&3Z5,KI.PUOJ>?VEZMMH+SM8:;'(E[F8&S.;1B6Y:,')(X
M((X/H.:;LH\K[_\ #>7F*UW*_EI]WW_J:QU2:6ZMKV>PLMUNL"RMMWR!ICC]
MV^> ,@]\YJDES-=W;[E?_@?B*]UZ*_Y_CI^A+J=Q'9:BOD:?9^1IB1N2T0WJ
M)&*XC/\ #@#/OT]ZE.WO/T_KRU0Y;6]7]WZO4DT"]\V\W&SM8!?Q&Z0P1[6(
M# ?.?XC@@YX[CWII6C;M;\;_ .02TE]Z^XZ.D!%/_JQ_OK_Z$* "?_5C_?7_
M -"% $M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 17/_ !ZS?[A_E0!+
M0!$W_'U'_N-_-: ): *UOJ%G=7$]O;W44LUN=LJ(P)0^]"U5T#T=F/22VD!N
M4>)PH*F0$'&#R,^Q'/THV5PZV(O[4T_[/%<"_MO)E;9')YJ[7;T!SR:+:V#I
M<E%W;&[-H+B(W(7>8MXWA?7'7%"UV#8!=VQNC:BXB^T!=YBWC>%]<=<4>8;!
M;7=M>1F2UN(IT!*EHW# $=1D=Z/,.MB:@ (R,'I0!P.DY\*^-YM+8[;&_P#F
MAST!_A_7*_E7?4_?45/JCCA^ZJ\O1G?5P'8% !0 4 % !0 4 % !0 4 % !T
MH Y74;V?7KW^S-/;%NI_>R]C_P#6_G7FU:DL1+V5/;JR&[Z(Z&QLH=/M5MX%
MPJ]2>I/J:[J=.-./+$I*Q9K09DZ]I(U*SW1C%S%S&?7VKFQ-'VL=-T3)7&^'
M]6_M"U\F8XNH>'!X)]_\:6&K>TC9[H(NYL5U%!0!$EU;N<)/&Q] X-2I1>S"
MXZ::*WB,DTBQHO5F. *;DHJ[#8YZX\2RW,_V;1[8SOW=AQ^7]37#+%N3Y:*N
M1S=@67Q4V<P0K]2O^-">+?1![PPZ/K.J-C4KL10C^!._X#C\ZGV%:K_$E9!9
MO<V;#1[+30/L\(W_ -]N6_.NNG0A2^%%))%ZMAD<_%O)PY^4\(<,>.WO4R=H
MMCCNC@M)LKG4],?4H@[7;3ETN&NU7RE&\;3^[/(W,""A^]G/I4O=CKYW\_Z^
M0D[R:]/T_KK^I-:+:QM8%;.:*UB2V^T()P5W,W[K(*9;!()Y7J.#C M7YFOE
M\^77\-.OZDO;[W\KO_@OTN7M76&/5D$HN)T@CA-Z_F*N]3(?+W*%^;#9)P5X
M]>E1%J]WM?\ &W_#?AH7+X?D_NZ_U^))X::#[>66*5$FA+V>^0,!#OY  4;>
M2#@EN".>,!QNHV>^GY.WW:_\$4OC^_[]+_?_ %8ZFD!%/_JQ_OK_ .A"@ G_
M -6/]]?_ $(4 2T %&P&/IOB&+4S=M#:7'DP$A) H(EP!G&#P>>AQ_/!]E2!
MZ2Y?Z_K04>((?L?G&TN5F\_[.+8A?,,G7 ^;;TYSG&*.UNOZ;AWOT_6W^9.=
M8M!HXU/+F @87;\Y;.-N/7/&/6AZ-)=06M_+]-RNWB*W6W1Q:W+W#2-&;957
MS%91EL\XX'/7G(QG-%TM>F_RV_,/Z_KY&G;7$5W:Q7,#[XI5#HWJ",BFTXNS
M$G=$M(84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\'_&@ VS_P#/2/\ [X/^- !MG_YZ1_\ ?!_QH -L_P#STC_[X/\ C0 ;9_\
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MN''RXZTXN\;][?AM]_XA+XOO_'?^NAT=("*?_5C_ 'U_]"% !/\ ZL?[Z_\
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MQVIWLE)^=OT_5?YA:\I17E?^OZ^1I06]T6M;6:XAGDOQ;RB;[0C'$3;CWR_
M&"H/).<52TE;L[_@E^?X$=+KJFOQ?Z/[T7-6BFFU(Q&-(FU2.%%$LT:M$8W+
M-QN^;@\;<\]<=:A*_N^=_P %_D5+:_DU]Y)X<@D%\D;&(?V;;FT8I*KEV+ Y
MP"2O"CAL'D\52=XN7>WX7_S"?Q_>_O.HI 13_P"K'^^O_H0H )_]6/\ ?7_T
M(4 2T % '': LT>M:KINH7-R+V1BXD20E)4PO*Y^ZP!' Q@-[#!'6G;MO_7F
M.>D[]]OQ_KY#U%TIAL1=W)L+K4&2*4S,9/*$9; ?.[!=2 <YQWIKWK7[-_CI
M^#N)^[=KR_X/^7J2_P!H7;>$8F\]Q*]T+4SY^;9YWE[L^NWOZT6YG"_5)_A?
M\0^'GMTO;^O+]"M'+<7&I?V*UY<I:Q3S 3+,PD(5$95+]3@N>_.WG/-3?W>;
MJD_P=K_<-JSLNZ_%-G0Z#=RWV@6%U.<RRPJS'&,G'7\:TFK2)6EUVN:!. 2!
MGV%0,C\U_P#GWD_-?\: #S7_ .?>3\U_QH /-?\ Y]Y/S7_&@ \U_P#GWD_-
M?\: #S7_ .?>3\U_QH /-?\ Y]Y/S7_&@ \U_P#GWD_-?\: #S7_ .?>3\U_
MQH /-?\ Y]Y/S7_&@ \U_P#GWD_-?\: #S7_ .?>3\U_QH /-?\ Y]Y/S7_&
M@ \U_P#GWD_-?\: #S7_ .?>3\U_QH /-?\ Y]Y/S7_&@ \U_P#GWD_-?\:
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M_P : #S7_P"?>3\U_P : ) <@$C'L>U $=S_ ,>LW^X?Y4 2T 1-_P ?4?\
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M,DFFF..C5CBM)BC%A=6LL-^+2&8"UF2"19PP+84X'(7U(V_-@U3;<4_M:_\
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MX7UQUQ1YAL%M=VUY&9+6XBG0$J6C<, 1U&1WH\PZV)J (+FSM[Q EQ"LJ@Y
M8=#42A&:M)7%:Y2/AW22,&S7\&8?UK)X6B_LBY47+2QM;%-EM L8[XZGZGJ:
MUA3A35HJPTK$[*&4JP!4C!![U>PS@=/8^#O&,FG2$C3;\@Q$]%/;\CQ^1KT)
M_OZ7,MT<<?W-3EZ,[^O/.P* "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * &3'$$A\P1?*?G/\/'6IEL[#CNC@[34KC3='U"P:2\:^4MON
M(Q)<( =W[Q2 2I.",' !Y^I4=X::;_\ #7_I[CBK3UUO;^K?UV+$.HW,R6]T
M+NX$D2V:QQ,642;VPY93][//)],BMFOWC]6OE:_R_I&,7>FK_P M_G?_ (;[
M_0O:W=7$>J7#I<RQFUCMV@B5R%D9Y"K9'1L@ <],^M9+35=[?*W_  _W&DMO
MDW\U_7XB^';JXDO+<R7,LQNK1IYU=RPCDW@  ?PCDC _N^N:I)6:[<OXIW"6
MDOG+\&K'44@(I_\ 5C_?7_T(4 $_^K'^^O\ Z$* ): "@#E=&L;ZU\1ZG<I8
MR6EG)DO#O4K+)A<,@_[ZR3C.1W!P1TIM?<.6LU;[Q+2PU"+1]+E:PD%S87+R
M-;F2/<ZL''!#;<X?/)'2A>[;_#;\OU7W$[J2\[_C?\G]Y+_95ZOAY+3R";I)
MA><.NPOYWF&/.<Y[9QCWIWY7&WV;+UTLQ_%S7^U?Y=OZ]2%--U*WO?[92Q:2
M>2:5FM?,0,BLB*O.=N?W8S@]SC.*FS4>7NG^=QWN[ONOP5OU-[1K%]-T:SLI
M&#/#$JL1T)QSBKDTWH2KO5]=?O+I&00>_IQ4C*=]+;Z=8S7<YE\J%=S;78G'
MYU48N344*345=F5H_B;2M;O3:VANO,"%_G) P,>_O6M3#SIJ\C.%:,W9&[Y"
M>LG_ '\;_&L#4/(3UD_[^-_C0 >0GK)_W\;_ !H YOQ=KDOAV&U>WB\TS,P(
M>1^,8]#[UTX>BJK:;,*U5TTFA/#OB.WU+2'O=3FALL3F)=UP5!PH/\1Z\U&(
MIQHRM<TP[G73<5]QNVMQ87RL;.\2X"<,8K@OCZX-8)I[&TJ<X?$K%CR$]9/^
M_C?XTR \A/63_OXW^- '">(?&5UHVNW-A#;(Z1;<,TCY.5!]?>N^CA8U(*39
MR5,0X2<4B6]\=0Z;'9">QEDDN+9)R4G8 ;L\<_2O.K35*;@>OA,)+$TO:)V.
MKTN>/4]+MKY5EC$Z!PIE8X_6G%W5SGJP]G-P[%OR$]9/^_C?XTS,/(3UD_[^
M-_C0!XGI0!\660YQ]M0=?]L5[D_X3]/T/)C_ !%ZGHJ^-=#?45L0;SSC+Y0Z
MXW9Q_>]:^>]K&]CZ/ZC54.?2VYT_D)ZR?]_&_P :U.(/(3UD_P"_C?XT <_X
MWA5/!]^07R/+ZN3_ ,M%]ZZ<+_%7]=##$?PV<#X7)6RUYU9D=+!RI5B"#^%=
M&8?PA98DZZ3\BS\/[NYNO$XCGNIY$\ES@RM[>]>'1;<CZ?,(1C1NEU/5?(3U
MD_[^-_C76> 'D)ZR?]_&_P : ,#Q+X@@\-_9=]O-/]HW8VSE<;<?XUT4:#K7
ML]C&K55.UT6/#FK0^(=/DNTAE@"2F/:9F/0 Y_6IK4G2ERME4ZBJ*Z-?R$]9
M/^_C?XUB:!Y">LG_ '\;_&@ \A/63_OXW^- !Y">LG_?QO\ &@ \A/63_OXW
M^- !Y">LG_?QO\: #R$]9/\ OXW^- $@&T #MZT 1W/_ !ZS?[A_E0!+0!$W
M_'U'_N-_-: ): .,TUET_5=35+"YEL(\R['M69XY"5.U"!\P)YXSC:#GD41=
MH?=;_@^G<<E[_P"?X_F3LL<GAN[L;>&X\^Y\V;RWMY(@^6W,HW >N!G&>31M
MR]E;[K_UIZ"NW=]7=?.VG_#E"XMIWO;Z^&G7+VEW'-%;Q>0VX.R1J"5QE02K
M<G&._6BSY7'J_P -6_\ )_\ !*37-&716O\ =^FW_ +5K:W-KJ,*36TYF@NF
MN99UB9E:/R=O# ?,<X&T9/'2J35[^OXRNC-)I6>[Y?P2O^OWD=]87EU<7-M;
M6TR7+W$LXG*%5*- 57YNF<D#;U&*SM[MGT3^=Y7_ "-(M*5WU<?E:U_3K]YK
M^'XV-S=7"VLMM;M%#&L<D9C.Y5(8X/U SWQ6K=[ONV_R,HIJR[)+\6;U061;
M9_\ GI'_ -\'_&@ VS_\](_^^#_C0 ;9_P#GI'_WP?\ &@ VS_\ /2/_ +X/
M^- &/XC\/?V_IWD221K-'EHGV$8/IUZ&MJ-5TI7Z&56FJD;&3X5\079N&T+5
M76*_M_E0R+DR =LYZX_,5M7HJWM(;,SHU'?DGN==MG_YZ1_]\'_&N,Z0VS_\
M](_^^#_C0 ;9_P#GI'_WP?\ &@ VS_\ /2/_ +X/^- !MG_YZ1_]\'_&@ VS
M_P#/2/\ [X/^- !MG_YZ1_\ ?!_QH -L_P#STC_[X/\ C0 ;9_\ GI'_ -\'
M_&@ VS_\](_^^#_C0 ;9_P#GI'_WP?\ &@ VS_\ /2/_ +X/^- !MG_YZ1_]
M\'_&@ VS_P#/2/\ [X/^- !MG_YZ1_\ ?!_QH -L_P#STC_[X/\ C0 ;9_\
MGI'_ -\'_&@ VS_\](_^^#_C0 ;9_P#GI'_WP?\ &@ VS_\ /2/_ +X/^- !
MMG_YZ1_]\'_&@!Z!P/G8$^PQ0 2!S$XCV[\';NZ9]ZF5[.PU9/4X71HKBWT#
M4[6$/'?I(SW$$5O"&))8?*2-K(<>A. 1UP Y6Y%;;^M_^!N$;JH[[_UM_P '
MYEEKSS+FVOXOL[1V:6L<8%NHWB4@,02-RC!& ,=.<UI;WW?JVOPN9KX$NRO^
M:_0FU9A;:F7MX;>./2HX7CC\A#GS'*D XRO XVXYZ^E9IV][SM^"_P RY;6\
MF_N_K4D\-SN;U)&$7_$RMS=L$B5"C!@,9 RW##ELG(/TJDK1<>UOQO\ Y!/X
M_FU]QU-("*?_ %8_WU_]"% !/_JQ_OK_ .A"@"6@ H * "@#DKMY[+QW!+>S
M3?9;A-ELT;G;&<J"CKTP3W_VATP**?VD]_\ A_Z^03V36W_!.EM+^SOT9[*[
M@N50[6,,@< ^AQ1TN&SL6* &NXCC9ST4$G% &;K5O/J.BW=G#"5DFC*J7( !
M]^:TIR4)J3(G'FBTCB]*\#ZO8B_$OD'[1:20+MDZ,V,9XZ<5T8JO&M3Y8D8.
MFZ%95);(E\+>$M3\.:N=1O?):!(F!\M\D?@0/2O+A3<'S,]O%XVG6I\L4SKK
M;Q#87EPMO;F1Y6SA=N,X&>].&(I3ERQ>IY*DF7S.RE08),L<#E?\:W&<UXQT
M&^\0P6B6B*AA9BWFL!G('3&?2NK#UHTFW(PK4W422,"3P-K#^&X].'D><MTT
MQ/F?+M* >G7(K#&26(DG$[LMJ+"7Y^O8U?"VFS^#;&[;52FR9UVM$=V, ]:Y
M$U0C>;-\;B85VG'H=+9:Q;:CYGV19)/+QNX QGIU/M5TZT*M^1G FGL6O/;<
M5\B3( )&5_Q]JU&<#XD\&:MK&OW-_;B%8I=NT2/AAA0.P/I7H4<5"G!1:9QU
M</*<W)$&L^!=8U V)A\A?L]HD#;I,99<YQQTYKR\1!U:CDCWL#BX8:C[.:=_
M(ZFPOX/#FE66FZ@2MQ%",[!N!Z\@_A6;K4Z-HS>IPUZD9U')=38MKY+RW6>W
MBD>)LX;@9P<=S6T)QG'FCL9IW)%G9AE8)",D=5[?C5 >=67@76+;7;>^?R#%
M%<K*0).<!L^G6O2EBX.#C9['"L/)3YAD7@/64\0)?DV_E+=";'F'=C=GTZUX
MGL9<USZAX^DZ7)9WM;\/4[:7Q-IL$SQ2-(KHQ5ALZ$=:;Q5*+LW^9X?,C2:=
MD&3!(!D#JO?\:Z"C+\26-SK&@7-A;Q;99=NTR, HPP/8GTK6C-4YJ3,ZL'.#
MBCEM'\&:MI]KJD4HA+7=JT*;7X#'UXZ5MBJT:T.6(L'!T*JG+8/"_A/4O#6J
MMJ5\83;QPON\M\D>^,#TKRXP=/WI;'M8O&TZU/EBF==:^(+&]G$%N9'D.2!M
MQ_.JAB*=1\L7J>2FF7_/8,%\B3)&0,K_ (^];C.6\9^'[_Q%]B^R(B>1OW>:
MV,YVXQC/H:Z\-6C2OS=3GKTG4M8Q)/ VL/X;CTX>1YRW33$^9\NTH!Z=<BN?
M&26(DG$[\MJ+"7Y^O8V?#-I)X-TB6+52H\Z?<K1'</NCC]#7(I1H1]]FN-Q$
M*TU*/8Z*RU>WU%7-JLD@3 ;@#'YFM*=6%36#.)-/8LB=B6 @DRIP>5_QK08O
MFO\ \^\GYK_C0 >:_P#S[R?FO^- !YK_ //O)^:_XT 'FO\ \^\GYK_C0 ]'
M$D:N.C $9H 9<_\ 'K-_N'^5 $M $3?\?4?^XW\UH EH IIJNGR/=*M[ 3:?
MZ_\ >#]WQGYO2B^E^@[:VZDR/;R(MVC1NA3*S @@J>>#Z=Z'[NXEKL1?VII_
MV>*X%_;>3*VR.3S5VNWH#GDT6UL'2Y*+NV-V;07$1N0N\Q;QO"^N.N*%KL&P
M"[MC=&U%Q%]H"[S%O&\+ZXZXH\PV"VN[:\C,EK<13H"5+1N& (ZC([T>8=;$
MU !0 4 % !0 4 <SXL\-?VO MY9?N]2M^8V4X+XYQGU]#73AZWLWRRV9A6I<
MZNMT95OXXU*S@2+4M!N3(@P\H!7<?7!7C\ZV>%A)WA)&:KR2M*)<LOB)I-S<
M+#/'-:Y.-\@!4'WP?Z5$L'.*NM2HXF#=GH=:CK(BNC!D89#*<@BN/8Z1U !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $<^W[/)NC,B[3E ,[ACI
M4RTBQQW1Q6CQ"\T.>ZM-,9VDE9SC4Y$R 6^5F^\,=-N".?KBI>[%7V_K[_F)
M:R:6FR]/\OD6_MVG3W=E=II9$,<=ON<RE/*WG$8\L<-M)ZGIGBKL^=KS:^=O
MPTTO\B=XKR5_E?\ ':_RN3ZF]C;ZI"'L'N%LDC:69KA\HK.0F0<^9@@GYNG4
M<U$79W^7SM_P=_,J6WWOY=?^&VT)/#\]F]Z[0V'V;[5&9H7,Q??&&YX/"<G.
MT<?-ZTXJT;=K?CM_70)?%]_X;_UU.CI 13_ZL?[Z_P#H0H )_P#5C_?7_P!"
M% $M &'JNNS6.M6&FV]LDLESECODV94 Y"\<MQWQV]<@C[TFNP/2-_ZZ?YEB
M?5VC2_D@LWGCLE.XAPI9P 2HSZ \G\.:F4N6'-_7F-*\E'^O(KW/B%XK>U>"
MQ,\DMM]KD3S-NR, 9P<<MSP.,X/(JY)0E)/9;_U\B8/GBFMWL0:E!IZWMAJL
M%L;F]N6"V\;3%8V8KNWD<@$*O7!/Z8+.$G%;_P"6_P"?X^;"ZE'F>W]6%D\5
M#[.LL%DTGEPM/=*9 #"JL58#@[CD-QQG:>:-+^6GX[?\'L.SVZZ_A_6AJV6H
M"[EGA:/RY82"1G(9#]U@?0X/X@T6TO\ U<5[EQE#J589!&"*0Q: "@"O?_\
M(/N?^N3?R-14^!B>QPGAG_D8;7_@7_H)KQ<)_&C_ %T,X[GH14$J2.5.17NF
MHM !0!@^+O\ D"C_ *ZK_(UQ8W^$3+8H^"?^7[_@'_LU8Y?]KY?J3 ZO: Q;
M') !_P _C7IF@M !0!Q'C'_D+Q?]<!_Z$U>/C_XB]/\ ,SGN=#X9_P"1>M?^
M!?\ H1KNPG\&/]=2H[&JJA!A1@9)_.NHH6@ H \QU3_D+WO_ %W?_P!"-?.U
MOXDO5F+W/364,,$9&0?RKZ(V%H * *FJ?\@B]_ZX/_Z":RK?PY>C$]CB_"W_
M "'H?]UOY5Y."_BHSCN=]M&X-CD# _S^%>V:BT % '-^,O\ D&P?]=?Z&N#'
M_P ->I$]B+P7_J+S_>7^1J,!\,@@=0%"EB!RQR:](L6@ H * "@!%4(H51@
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M 'E/_P _$GY+_A0 >4__ #\2?DO^% !Y3_\ /Q)^2_X4 'E/_P _$GY+_A0
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MV*U:*WG@+W5N\%V[Y&W<Y8L@P<XWL,'';GBE9?#TT_#_ #_ KF:?-UNW]_\
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MN5T.015--.S)33V):0PH * "@ H * "@ H * "@ H R=3\-:3JV3=6:&0_\
M+1/E?\QU_&M85IP^%F<J4)[HYM_!VL:,QE\/:LX7KY,IQG_V4_B!75]8IU-*
ML3#V,X?PV+'XVU+29%@\0Z3)%V\V(<'\.A_ TGAH3UI2!5Y0TJ(ZC3=<TW5T
MS97:2-W3.&'X'FN6=*=/XD=$:D9_"R])+'"FZ618U]6.!4)-[%WL4/\ A(=&
M#E#JUF"/6=?\:T]C4_E9'M(=R9-5TZ0934+9AC.1,IX_.I=.:Z#YHOJ!U?35
M4EM0M0!U)F7C]:/9S[!SQ[DD%_9W(!@NX90>FR0-_*DXR6Z&I)[,L5(PH *
M"@ H * "@ H * "@!K[O+;80&QP6&0#[TGL-;G%:987-[I&LI8RV!%Q*46"&
MY+11L&.YLA?E)&. .V>]4M(Q\G?Y+H3+64D^UOO1L7>CWMS?,X:!+>X:"2?Y
MR61HSG"\<@X R<8QTYHC[K^;?X6_X(.[7G:W]?>Q+[1[Z]NG?,$<=W'$ER-Y
M)38Q;Y/E&[.<<XQUYZ4DEL]KW^?])#EJM.S7R8_1M&NK&YB:X>(Q6L!MX/+)
M)92P.YL@8. !@9[\TT]'?=V_"_\ F$M97]7]_P#D;M("*?\ U8_WU_\ 0A0
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M 'FO_P ^\GYK_C0 >:__ #[R?FO^- !YK_\ /O)^:_XT 'FO_P ^\GYK_C0
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M^- !YK_\^\GYK_C0!(#D D8]CVH CN?^/6;_ '#_ "H EH B;_CZC_W&_FM
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M":RK?PY>C$]CB_"W_(>A_P!UOY5Y."_BHSCN=_7MFH4 % !0 4 % !0 4 %
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MQ>Q6K16\\!>ZMW@NW?(V[G+%D&#G&]A@X[<\4K+X>FGX?Y_@5S-/FZW;^_\
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MBA<E1CC##C&23UH Z/3-)M=,1G@B9))@#,6D+%V[L>Q;GD]^/04 :% !0 4
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M0 >:_P#S[R?FO^- !YK_ //O)^:_XT 'FO\ \^\GYK_C0 >:_P#S[R?FO^-
M!YK_ //O)^:_XT 'FO\ \^\GYK_C0 >:_P#S[R?FO^- !YK_ //O)^:_XT '
MFO\ \^\GYK_C0 >:_P#S[R?FO^- !YK_ //O)^:_XT 'FO\ \^\GYK_C0 >:
M_P#S[R?FO^- !YK_ //O)^:_XT 'FO\ \^\GYK_C0 >:_P#S[R?FO^- !YK_
M //O)^:_XT 2 Y )&/8]J ([G_CUF_W#_*@"6@")O^/J/_<;^:T 2T % !0
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MKUZC@ Z?2K6>SL$AN'B+KT6%2J(.RJ#V Q0!=H * "@ H * "@ H * "@ H
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MN6&+>^@E>.Y@OY& 7"C]T #CG@AN>N<'- '7QL7C5BI4D E3U'M0 Z@ H *
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M * "@ H * "@ H * "@ H * (I_]6/\ ?7_T(4 $_P#JQ_OK_P"A"@"6@ H
M* "@ H * "@#/O[RZ25;6QA5[E\'=+D(J_-DG')QM _X$* .<O(;F^</?V<B
MI<KM$MLIDDL[B,L-RX&XJ?4#Z]: -NRTZ6:>QU::1K>\:U5;J.,8$K8!PV?[
MIW8Z'GKVH UD1(HUCC4(BC"JHP /04 .H Q+W5K^,S36=I&UK:@M.96*LV&8
M,%QQD!=W/7(]: ,:"QNK+4;8+;2B^M+@1BXC0F.YMG?D.1P&4'/S=UXZT =!
MI>ESV<\UQ<W;32.SE(UXCC5G+8 [G)Y)_#% &I0!'<3+;6TL[*S+&A<A1DD
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M$P-W8'[R]3VH UM%T1+9([J9YVF)9MCMA02<[]G0,>"?0DXQ0!N4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 13_P"K'^^O_H0H )_]6/\ ?7_T(4 2T % !0 4 % #))4A3?(P
M5<@9/N<"@##.H?VVEQIZM<Z7,RJ]O*60-*I)PRC)./EY! .#[T %A?37MS;B
M>-4U.S=H;N(?W6'WU_V20A'XCJ* +FFZ,EA<SW4EQ+<7$K/\SG"HK,6VJHX
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M!!]: -1](6?5QJ$]Q*ZH%\N#.$5AGYCCJ>3UX% &G0 R66.% TC!5+!<GU)
M _,B@#"_M!M>MI;.-[G2KEE6:!G*AW7DJVW).,CD'!QP>M #M/OWO[JW=X1'
M?VY:WO(0W^KR,[AZ@E5P?1OK0!<TO1UTYI)GN)+FXDR"[\!5R2%51P!S]3W-
M &E0 4 <[KD\-IK>GS:E$KZ6T;QF1QF.*4D8+#H,C(R>F>V: ,S3(M$N'UC0
MK+4(7LY65X8XY-QA<C+;,'@ A2,=#GTH [&&+R84CWO)M&-SG+'W- $E !0
M4 % !0 4 % !0 4 17/_ !ZS?[A_E0!+0!$W_'U'_N-_-: ): "@# U+7+NT
MU!K"&WMS)*0MO(\^U<D<J_!*MQ\HQ@_G0!3T?1C>P*U]"V%R4N/,VS.&/SQR
M!>& (P3T/! H ZE$6.-410J*,*JC  ]!0!R6L^(+74=/C6&[\G3[I&#3 $.Y
M&040]GSC@@YR?2@#0T?0C!(;B]CB$F_<(HAB,N,@3!?X6(QD#I]: -^@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H BG_U8_WU_P#0A0 3_P"K'^^O_H0H EH * "@ H K3ZA:
MVMU;6TTRI-<DK$I_B(&30!CR"_22:/5;V+[%<P2EE"!?(QC!#9Y&T\Y[C\*
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M4!\Q695+;NH(+<?[OO0!$MO%J%E=6J06MV(;AA&;@90 GDC@_=)9<<?=QD4
M;%O:QV\,,8^=H8Q&KMRQ&!W]\"@":@"M-J%K;WMO9RS*D]QN\I#_ !8Y/^?8
M^E &*_\ :*>=#JE[$(+BTDE)V!?LK*5X!_B W=3W7WX +0LUU.:POVL[>-P%
ME>4C]\C#^ <=.2#SZC'.: -=8T0L415+'+8&,GU- #J ,J76[*<7UK9WJ&\@
MB=MHY*XR,\\'!X/ZT 5M$UPZFMUISRJ-4LQLF=%W1Y/W7'UZ[<Y'(H UK.V:
MVM%AEN)+EQG=)+C+$G)Z< >U %@  8 P* "@ H * "@ H * "@ H * "@"*Y
M_P"/6;_</\J ): (F_X^H_\ <;^:T 2T <WXAO+RPO(IY8_^)>,".19618Y<
M\-+C!V<X]/7J, #HO#_FZA+<2RVT]C<,9)(C%O9S@_(7)P4#$L..M &S-=6>
MFPQ+-+%;Q9$<:G"CT  _SB@#"UZ_NKEY;.SCE\JWD07!CDV-)G'[M6!RK'<,
M>N,9&02 /\+6MI);G489I9)7+(^]_FX/'F*#CS , GKQS0!T= !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0!%/_JQ_OK_Z$* "?_5C_?7_ -"% $M
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H BN?\
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MGN^IDV[F[K4*7?B&(6EU$FK6L'FP(7&6^;E2.NUAQ^O:O=BVG*2UVOZ:_P#
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MM,72;1K9+B:=3(TFZ7;D%CD_= '4D_C3OHEV#JWW+U( H * "@ H * "@ H
M* "@ H * "@ H * "@"*Y_X]9O\ </\ *@"6@""1TCN8R[!1L;DG'<4 .^TP
M?\]H_P#OH4 'VF#_ )[1_P#?0H /M,'_ #VC_P"^A0 ?:8/^>T?_ 'T* #[3
M!_SVC_[Z% !]I@_Y[1_]]"@ ^TP?\]H_^^A0 ?:8/^>T?_?0H /M,'_/:/\
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M]"@ ^TP?\]H_^^A0 ?:8/^>T?_?0H /M,'_/:/\ [Z% !]I@_P">T?\ WT*
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
, H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
